Ribitol is under clinical development by ML Bio Solutions and currently in Phase III for Limb-Girdle Muscular Dystrophy. According to GlobalData, Phase III drugs for Limb-Girdle Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ribitol LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ribitol (BBP-418) is under development for the treatment of limb-girdle muscular dystrophy type 2I. It acts by restoring alpha glycosylation substrate. It is an oral small molecule therapy.
For a complete picture of Ribitol’s drug-specific PTSR and LoA scores, buy the report here.